NEW YORK, Aug 16. – Proteomics company SomaLogic said Thursday it had signed a multi-year deal to provide Celera with early access to its aptamers and aptamer arrays.
In exchange, SomaLogic will receive access to Celera’s sequence data and proteins with which it can develop additional aptamers.
Aptamers are DNA or RNA molecules that have been artificially manipulated to bind with molecules and viruses. They are considered to have many potential uses in medicine and diagnostics.
SomaLogic's aptamer technology uses nucleic acids to bind to distinct proteins. Assembled in an array format, the company said its approach is designed to allow researchers to detect thousands of proteins and link them with particular diseases.
"SomaLogic's aptamer technology complements our genomics and proteomics programs by providing a unique approach for identifying expression and function of multiple proteins likely to play a role in major disease," Craig Venter, Celera's president and chief scientific officer, said in a statement.
"This agreement should strengthen our proteomics capability and helps our expansion in drug discovery," he added.
SomaLogic, of Boulder, Colo., was established in 1999. The company is also using its aptamer research to develop diagnostic tools.